DOCSLIB.ORG

Compilation of Abstract Titles from ASCO Annual Meeting 2021 (Oral, Poster Discussion, Posters, Mains Track by Cancer Types Only)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Compilation of Abstract Titles from ASCO Annual Meeting 2021 (Oral, Poster Discussion, Posters, Mains Track by Cancer Types Only) Bertrand DELSUC / Biotellytics / @bertrandbio Compilation of abstract titles from ASCO Annual Meeting 2021 (oral, poster discussion, posters, mains track by cancer types only) Table of Content I. ORAL PRESENTATIONS ............................................................................................................................................ 4 Plenary Session ........................................................................................................................................................... 4 Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology ...................................... 7 Lung Cancer—Non-Small Cell Metastatic ............................................................................................................ 10 Sarcoma ...................................................................................................................................................................... 13 Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant ...................... 15 Pediatric Oncology I ................................................................................................................................................. 18 Melanoma/Skin Cancers ......................................................................................................................................... 21 Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers .................................... 25 Breast Cancer—Local/Regional/Adjuvant ........................................................................................................... 28 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary ............................................ 32 Breast Cancer—Metastatic ..................................................................................................................................... 35 Central Nervous System Tumors .......................................................................................................................... 39 Genitourinary Cancer—Kidney and Bladder ...................................................................................................... 42 Gynecologic Cancer .................................................................................................................................................. 45 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia .......................................... 49 Gastrointestinal Cancer—Colorectal and Anal .................................................................................................. 52 Head and Neck Cancer ............................................................................................................................................ 56 Developmental Therapeutics—Immunotherapy............................................................................................... 59 1 Bertrand DELSUC / Biotellytics / @bertrandbio Genitourinary Cancer—Prostate, Testicular, and Penile ................................................................................. 62 Hematologic Malignancies—Plasma Cell Dyscrasia.......................................................................................... 65 II. POSTER DISCUSSION PRESENTATIONS ................................................................................................................. 69 Central Nervous System Tumors .......................................................................................................................... 69 Developmental Therapeutics—Immunotherapy............................................................................................... 72 Gastrointestinal Cancer—Colorectal and Anal .................................................................................................. 76 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary ............................................ 79 Genitourinary Cancer—Kidney and Bladder ...................................................................................................... 83 Genitourinary Cancer—Prostate, Testicular, and Penile ................................................................................. 86 Gynecologic Cancer .................................................................................................................................................. 90 Head and Neck Cancer ............................................................................................................................................ 94 Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant ...................... 97 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia ........................................ 100 Hematologic Malignancies—Plasma Cell Dyscrasia........................................................................................ 103 Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers .................................. 107 Lung Cancer—Non-Small Cell Metastatic .......................................................................................................... 110 Melanoma/Skin Cancers ....................................................................................................................................... 114 Pediatric Oncology ................................................................................................................................................. 117 Sarcoma .................................................................................................................................................................... 120 Pediatric Oncology II .............................................................................................................................................. 124 III. POSTER PRESENTATIONS ................................................................................................................................ 127 Breast Cancer—Local/Regional/Adjuvant ......................................................................................................... 127 Breast Cancer—Metastatic ................................................................................................................................... 145 Central Nervous System Tumors ........................................................................................................................ 166 Developmental Therapeutics—Immunotherapy............................................................................................. 176 Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology .................................. 212 Gastrointestinal Cancer—Colorectal and Anal ................................................................................................ 242 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary .......................................... 265 Genitourinary Cancer—Kidney and Bladder .................................................................................................... 301 Genitourinary Cancer—Prostate, Testicular, and Penile ............................................................................... 320 2 Bertrand DELSUC / Biotellytics / @bertrandbio Gynecologic Cancer ................................................................................................................................................ 338 Head and Neck Cancer .......................................................................................................................................... 357 Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant .................... 375 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia ........................................ 383 Hematologic Malignancies—Plasma Cell Dyscrasia........................................................................................ 396 Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers .................................. 405 Lung Cancer—Non-Small Cell Metastatic .......................................................................................................... 421 Melanoma/Skin Cancers ....................................................................................................................................... 446 Pediatric Oncology ................................................................................................................................................. 463 Sarcoma .................................................................................................................................................................... 469 3 Bertrand DELSUC / Biotellytics / @bertrandbio I. ORAL PRESENTATIONS Plenary Session Sunday, June 6,7:00 PM - 10:00 PM CEST Back to Program Showing 17 Presentations https://meetinglibrary.asco.org/session/13668 Chair CHAIR Norah Lynn Henry, MD, PhD, FASCO, FACP | University of Michigan Chair CHAIR Lori J. Pierce, MD, FASTRO, FASCO | University of Michigan OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. AUTHOR(S) Andrew Tutt, Judy E. Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja,
Load more

Recommended publications
  • Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
    Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami) Media Release Copenhagen, Denmark and Lausanne, Switzerland, October 30, 2020 • ADC Therapeutics to continue the development and commercialization of Cami • Genmab to receive mid-to-high single-digit tiered royalty Genmab A/S (Nasdaq: GMAB) and ADC Therapeutics SA (NYSE: ADCT) today announced that they have executed an amended agreement for ADC Therapeutics to continue the development and commercialization of camidanlumab tesirine (Cami). The parties first entered into a collaboration and license agreement in June 2013 for the development of Cami, an antibody drug conjugate (ADC) which combines Genmab’s HuMax®-TAC antibody targeting CD25 with ADC Therapeutics’ highly potent pyrrolobenzodiazepine (PBD) warhead technology. Under the terms of the 2013 agreement, the parties were to determine the path forward for continued development and commercialization of Cami upon completion of a Phase 1a/b clinical trial. ADC Therapeutics previously announced that Cami achieved an overall response rate of 86.5%, including a complete response rate of 48.6%, in Hodgkin lymphoma patients in this trial who had received a median of five prior lines of therapy. Cami is currently being evaluated in a 100-patient pivotal Phase 2 clinical trial intended to support the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). The trial is more than 50 percent enrolled and ADC Therapeutics anticipates reporting interim results in the first half of 2021. “We have a long-standing relationship with the ADC Therapeutics team and believe they are an ideal partner for the ongoing development and potential commercialization of Cami,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
    [Show full text]
  • The Causes and Effects of the Development of Semi-Competitive
    Central European University The Causes and Effects of the Development of Semi-Competitive Elections at the Township Level in China since the 1990s By Hairong Lai Thesis submitted in fulfillment for the degree of PhD, Department of Political Science, Central European University, Budapest, January 2008 Supervisor Zsolt Enyedi (Central European University) External Supervisor Maria Csanadi (Hungarian Academy of Sciences) CEU eTD Collection PhD Committee Tamas Meszerics (Central European University) Yongnian Zheng (Nottingham University) 1 Contents Summary..........................................................................................................................................4 Acknowledgements..........................................................................................................................6 Statements........................................................................................................................................7 Chapter 1: Introduction .................................................................................................................8 1.1 The literature on elections in China ....................................................................................8 1.2 Theories on democratization .............................................................................................15 1.3 Problems in the existing literature on semi-competitive elections in China .....................21 1.4 Agenda of the current research..........................................................................................26
    [Show full text]
  • ADC Therapeutics SA (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2020. Commission File Number: 001-39071 ADC Therapeutics SA (Exact name of registrant as specified in its charter) Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ADC Therapeutics SA Date: July 6, 2020 By: /s/ Dominique Graz Name: Dominique Graz Title: General Counsel EXHIBIT INDEX Exhibit No. Description 99.1 Press release dated July 6, 2020 Exhibit 99.1 ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine Lausanne, Switzerland — July 6, 2020 — ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology, today announced that the U.S.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Educational Objectives Target Audience Abstract Instructions Services for the Disabled Language/Translation Cme Accreditation Cr
    TARGET AUDIENCE PROGRAM REGISTRATION This conference is designed for medical, surgical and radiation Tuition: US$350 Physicians in Practice (prior to June 21, 2004) oncologists, as well as obstetricians, gynecologists and other US$400 Physicians (On/After June 21, 2004 & On-Site) physicians interested in leading edge information on breast US$200 Residents, Fellows, Nurses and Allied Health cancer care and the most promising clinical trials for their breast Professionals cancer or high risk patients. US$130 Accompanying Person to Dinner Reception Tuition is complimentary for Patient Advocates / Cancer Survivors EDUCATIONAL OBJECTIVES Tuition includes, admission to scientific sessions, a course syllabus, continental breakfast, refreshment breaks, a cocktail reception on Upon completion of this conference, participants should be able Thursday, July 22nd, and a dinner event on Friday, July 23rd, to: 2004. Understand the basic mechanisms of the development of breast cancer, its natural history, risk factors, genetic There will be an additional $150 fee for each of the three Surgical component and prognostic indicators; Hands-On Sessions and $100 for the Nursing Seminar. It is required that attendees register for the entire conference in order to register Be up-to-date on today’s diagnostic and treatment for the surgical sessions and/or the luncheons. controversial areas of invasive and non-invasive breast cancer Refunds will be made only if written notice of cancellation is received care; prior to May 21, 2004. A $75 fee is charged for all refunds. After Guide patients to the ongoing clinical trials and develop May 21, 2004, no refunds will be made. In cases where a course novel treatment concepts for future clinical trials; is cancelled due to insufficient registrations, a full tuition refund is made.
    [Show full text]
  • Comparative Safety and Efficacy of Anti-PD-1 Monotherapy, Chemotherapy
    Lv et al. Journal for ImmunoTherapy of Cancer (2019) 7:159 https://doi.org/10.1186/s40425-019-0636-7 COMMENTARY Open Access Comparative safety and efficacy of anti-PD- 1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials Jia-Wei Lv1†, Jun-Yan Li1†, Lin-Na Luo2†, Zi-Xian Wang2* and Yu-Pei Chen1* Abstract Recent phase 1–2 trials reported manageable safety profiles and promising antitumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab and JS001) with/without chemotherapy in recurrent/metastatic nasopharyngeal carcinoma (RM-NPC), however head-to-head comparison among these regimens is lacking. We aimed to comprehensively compare the efficacy and safety of different anti-PD-1 drugs, standard chemotherapy, and their combination therapy in RM-NPC. Adverse event (AE) and objective response rate (ORR) were assessed. The pooled incidence rates of grade 1–5/3–5 AEs were 74.1%/29.6, 54.2%/17.4, 92.3%/24.5, 96.8%/16.1, 91.2%/42.8, and 100%/87.9% for pembrolizumab, nivolumab, JS001, camrelizumab, chemotherapy and camrelizumab+chemotherapy, respectively, which suggested that nivolumab and pembrolizumab exhibited the optimal safety regarding grade 1–5 AEs whereas camrelizumab and nivolumab regarding grade 3–5 AEs. As second- or later-line therapy, ORR was higher with camrelizumab (34.1%), followed by pembrolizumab (26.3%), JS001 (23.3%), and nivolumab (19.0%); whereas ORR with first-line nivolumab reached 40%. Additionally, first-line camrelizumab+chemotherapy achieved a dramatically higher ORR than that with chemotherapy alone (90.9% vs.
    [Show full text]
  • REVISTA DE HISTORIA MODERNA ANALES DE LA UNIVERSIDAD DE ALICANTE N.A 11 1992
    REVISTA DE HISTORIA MODERNA ANALES DE LA UNIVERSIDAD DE ALICANTE N.a 11 1992 ASPECTOS DE LA VIDA COTIDIANA EN LA ESPAÑA MODERNA (II) La presente publicación ha sido realizada en el marco del proyecto de investiga­ ción concedido por la Dirección General de Investigación Científica y Técnica del Ministerio de Educación y Ciencia a este Departamento de Historia Moderna (Na de referencia del proyecto PB90 - 0565) REVISTA DE HISTORIA MODERNA REVISTA DE HISTORIA MODERNA N911 ANALES DE LA UNIVERSIDAD DE ALICANTE (Revista fundada por Antonio Mestre Sanchis) CONSEJO DE REDACCIÓN Director: Enrique GIMÉNEZ LÓPEZ Secretario: Armando ALBEROLA ROMA Consejo de Redacción: Ramón BALDAQUÍ ESCANDELL David BERNABÉ GIL Mario MARTÍNEZ GOMIS Cayetano MÁS GALVAÑ Primitivo PLA ALBEROLA Jesús PRADELLS NADAL Juan RICO GÓMEZ María José BONO GUARDIÓLA SECRETARIADO DE PUBLICACIONES UNIVERSIDAD DE ALICANTE Impresión y 'Fotocomposictán: Imprenta de la Universidad de Alicante Depósito Legal: a - Si - i982 REVISTA DE HISTORIA MODERNA ANALES DE LA UNIVERSIDAD DE ALICANTE NQ 11. 1992 ASPECTOS DE LA VIDA COTIDIANA EN LA ESPAÑA MODERNA (II) ALICANTE, 1992 ÍNDICE I. INDIVIDUO Y COLECTIVIDAD Jorge DEMERSON Niños y jóvenes en las Pitiusas del siglo XVIII 11 Ramón BALDEQUÍ ESCANDEL y Jesús PRADELLS NADAL La familia de don Leonardo Soler de Cornelia. Un linaje de caballeros en Elche durante el siglo XVIII 25 Verónica MATEO RIPOLL Matrimonio y modo de vida de una familia de la pequeña nobleza periférica: Los Bourgunyo de Alicante 67 Leonor MALDONADO Negocios e integración social del comerciante marsellés Pedro Choly 79 José MALLOL FERRÁNDIZ Joaquín de Lacroix y Vidal: Un ingeniero de Marina ligado a la Real Sociedad Económicas de Amigos del País de Valencia 95 I.
    [Show full text]
  • Clare M. Wilkinson-Weber
    Clare M. Wilkinson-Weber TAILORING EXPECTATIONS How film costumes become the audience’s clothes ‘Bollywood’ film costume has inspired clothing trends for many years. Female consumers have managed their relation to film costume through negotiations with their tailor as to how film outfits can be modified. These efforts have coincided with, and reinforced, a semiotic of female film costume where eroticized Indian clothing, and most forms of western clothing set the vamp apart from the heroine. Since the late 1980s, consumer capitalism in India has flourished, as have films that combine the display of material excess with conservative moral values. New film costume designers, well connected to the fashion industry, dress heroines in lavish Indian outfits and western clothes; what had previously symbolized the excessive and immoral expression of modernity has become an acceptable marker of global cosmopolitanism. Material scarcity made earlier excessive costume display difficult to achieve. The altered meaning of women’s costume in film corresponds with the availability of ready-to-wear clothing, and the desire and ability of costume designers to intervene in fashion retailing. Most recently, as the volume and diversity of commoditised clothing increases, designers find that sartorial choices ‘‘on the street’’ can inspire them, as they in turn continue to shape consumer choice. Introduction Film’s ability to stimulate consumption (responding to, and further stimulating certain kinds of commodity production) has been amply explored in the case of Hollywood (Eckert, 1990; Stacey, 1994). That the pleasures associated with film going have influenced consumption in India is also true; the impact of film on various fashion trends is recognized by scholars (Dwyer and Patel, 2002, pp.
    [Show full text]
  • 2015 Post-ASH Report
    Datamonitor Healthcare Trialtrove Biomedtracker Pharma intelligence | Pharma intelligence | Pharma intelligence | 2015 Post-ASH Report RACHEL MEIGHAN-MANTHA Principal Analyst, Citeline JOSEPH HEDDEN Senior Analyst, Datamonitor Healthcare Summary Profiled themes at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), held December 5-8, 2015, in Orlando, Florida, included Genomic Profiling and Chemical Biology, Genome Editing and Gene Therapy, Epigenetic Mechanisms, Immunologic Treatments, Stem Cell Biology and Regenerative Medicine and Preventing Venous Thromboembolic Disease. This report will mainly focus on the theme of Immunologic Treatments because of the importance and popularity of immunotherapies for many different hematological cancers. Also covered in this report are the results from pivotal trials presented at ASH, as well as highlights from other drugs/therapies of interest. In addition, we felt it was important to cover first-in-human trials since (hopefully) some of these drugs/therapies will be in pivotal trials in a few years. At the end of the report, we’ve included a section showcasing drugs that had top- line results presented at ASH, followed by a list of other data presentations supplied by BioMedTracker (BMT). Accompanying links to BioMedTracker events along with changes to the drugs’ likelihood of approval (LOA) are also provided throughout the report. Finally, additional supplemental material related to ASH is listed in the Appendix. 2 Datamonitor Healthcare Trialtrove Biomedtracker
    [Show full text]
  • 3 Billionaires in Indiana See Net Worth Jump $2.3 Billion Or 17.2% in First Three Months of COVID-19 Pandemic
    EMBARGOED FOR RELEASE ON JULY 15, 2020 AT 12:00 AM 3 Billionaires in Indiana See Net Worth Jump $2.3 Billion or 17.2% in First Three Months of COVID-19 Pandemic Meanwhile State & Local Government Services Face Deep Cuts as Congress Stalls on New COVID-19 Financial Aid Package WASHINGTON—Indiana has 3 billionaires who collectively saw their wealth increase by $2.3 billion or 17.2% during the first three months of the COVID-19 pandemic even as the state’s economy was reeling from a huge spike in joblessness and a collapse in taxes collected, a new report by Americans for Tax Fairness (ATF) and Health Care for America Now (HCAN) shows. Between March 18—the rough start date of the pandemic shutdown, when most federal and state economic restrictions were in place—and June 17, the total net worth of the state’s 3 billionaires rose from $13.5 billion to $15.8 billion, based on an analysis of Forbes data. Forbes’ annual billionaires report was published March 18, 2020, and the most recent real-time data was collected June 17 from the Forbes website. This $2.3 billion increase in wealth is 60% of the projected $3.7 billion state revenue shortfall in fiscal years 2020 and 2021 combined due to the ​ ​ pandemic. Two Indiana billionaires—Carl Cook and Herb Simon—saw their wealth grow by 26% and 11%, respectively, during the pandemic while 741,000 of the state’s residents lost their jobs, 41,000 ​ ​ fell ill with the virus and 2,500 died from it.
    [Show full text]
  • Catalogue Produced on 22/03/2011 Si Buscas Música Flamenca, Video O DVD, Por Favor Visita: Flamencosound.Com
    Catalogue produced on 22/03/2011 Si buscas música flamenca, video o DVD, por favor visita: flamencoSound.com Video & DVD ........................................................................................................................................................................ 2 DVD ................................................................................................................................................................................... 2 Videos ............................................................................................................................................................................. 97 Phone Number: (0034) 91 5427251 - We export Flamenco worldwide. Torero. Antonio Canales. Dvd 14.95 € 21.23 USD Lanzamiento: 15/10/2010Hay un antes y un después de la obra ''TORERO'' tanto para mí, como para la danza flamenca en general… En ese momento es cuando nace el verdadero Antonio canales director, corógrafo, iluminador… en fin; un personaje más amplio y plural… más Renacentista y comprometido. Los papás del Torero en toda su concepción y realización somos dos entusiastas y soñadores, el señor Lucho Ferruzzo y mi persona… ''TORERO'' es un canto eterno, una evocación a la magia y el misterio que encierra la tauromaquia, filtrada por el fogoso y desgarrado lenguaje del flamenco. Con ello conseguimos, si cabe, dignificar aún más nuestra Fiesta Nacional y consolidar, a su vez, el Universal e inagotable Arte Flamenco. Con ella fuimos a los premios Emmy en Nueva York, conseguimos el Filpa
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]